The past 5 years have seen increasing application of health-related qu
ality-of-life (HRQOL) assessment in oncology. Most commonly, HRQOL has
been studied in patients with metastatic cancer and in trials involvi
ng the use of antiemetics to control postchemotherapy nausea and vomit
ing. These studies have produced interesting and, in some cases, count
erintuitive results. Thus far, HRQOL assessment appears to be importan
t in clinical trials involving control of symptoms (disease-related or
treatment-related), cancers with a poor prognosis, treatment arms wit
h similar survivals, supportive care interventions, and ways of determ
ining prognosis.